Avant Technologies Inc Stock Price, News & Analysis

Avant Technologies (OTCQB: AVAI) has issued a retraction of its September 24, 2025 press release regarding a purported Joint Venture and License Agreement with Art-Islets Pte. Ltd. and Austrianova. The company clarified that no binding agreement has been executed between the parties at this time.

The company acknowledged that the previous announcement contained statements issued in error and emphasized that any descriptions of collaborative activities, technology contributions, or anticipated clinical development milestones from the retracted release should not be relied upon. Avant Technologies expressed regret for any confusion caused and reaffirmed its commitment to providing accurate information to stakeholders.

Avant Technologies (OTCQB: AVAI) has formed a strategic Joint Venture with Art-Islets and Austrianova to develop innovative diabetes treatments using encapsulated stem cells. The collaboration combines Art-Islets' stem cell differentiation expertise with Austrianova's cell-encapsulation technology to create therapies for type 1 and insulin-dependent type 2 diabetes patients.

The partnership includes exclusive licensing agreements and plans for a potential U.S.-based entity to support clinical trials. Avant will provide initial funding over eight months to achieve the first three milestones, with additional funding planned to advance toward Phase 1 clinical trials. Art-Islets contributes its proprietary differentiation system for transforming ESCs into insulin-producing cells, while Austrianova brings its GMP-grade manufacturing expertise backed by over 50 peer-reviewed publications.

Avant Technologies (OTCQB: AVAI) and Austrianova have formed a joint venture called Klothonova, Inc. to develop cell-based therapies using encapsulated Klotho-producing cells. The 50/50 partnership combines Austrianova's proprietary cell-encapsulation technology and expertise with Avant's capital and resources.

The venture aims to develop treatments for Alzheimer's disease, heart disease, cancer, kidney disease, and age-related conditions. Austrianova brings significant expertise backed by over 50 peer-reviewed publications and global partnerships, while focusing on the therapeutic properties of Klotho, an 'anti-aging' protein discovered in 1997 that plays a crucial role in modulating aging and various physiological functions.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have announced an enhanced patient recruitment strategy for their upcoming FDA clinical trial of the Vision AI platform, designed for early detection of diabetic retinopathy. The study will be conducted across 8-10 U.S. clinical sites, targeting approximately 1,000 multiethnic patients with diabetes.

The companies will collaborate with Fortrea, a renowned Contract Research Organization specializing in ophthalmology studies. The trial will focus on community clinics and primary care facilities rather than specialized centers to gather real-world data. This strategic approach aims to support the company's FDA 510(k) submission for Vision AI, with Ai-nova Acquisition Corp. (AAC) holding worldwide licensing rights for Ainnova's technology portfolio.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have announced updates to their clinical trial protocol following FDA feedback for their Vision AI platform. The revised protocol, focused on early detection of diabetic retinopathy, will be resubmitted to the FDA for review.

The companies are working through their Contract Research Organization, Fortrea, to advance the protocol that will enable initiation of a new clinical trial. The technology is being developed under Ai-nova Acquisition Corp. (AAC), a partnership between Avant and Ainnova, which holds worldwide licensing rights for Ainnova's technology portfolio.

Avant Technologies (OTCQB: AVAI) announced that Vinicio Vargas, CEO of their joint venture partner Ainnova Tech, presented at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Colombia. The conference focused on scientific advances in treating common eye diseases and fostering regional collaboration.

Notably, Ainnova formed a strategic alliance with Roche and Salud 360 in Q4 2024 to launch a pilot program using their AI-powered Vision AI technology to combat diabetic retinopathy. If successful, the program could expand to the United States, Canada, and Europe through Ai-nova Acquisition Corp. (AAC), which holds worldwide licensing rights for Ainnova's technology portfolio.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have completed a crucial pre-submission meeting with the FDA regarding their Vision AI platform for early detection of diabetic retinopathy. The meeting provided essential guidance for their upcoming U.S. clinical trial, including protocol requirements and necessary resources.

Through their joint venture company Ai-nova Acquisition Corp. (AAC), which holds worldwide licensing rights to Ainnova's technology portfolio, the companies are preparing to conduct data collection across U.S. primary care clinics. The study will compare their AI-based retinal screening against readings from three retinologists. The trial's success is crucial for obtaining FDA 510(k) clearance to market the technology in the United States.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have launched an innovative preventive care model in Latin America, focusing on diabetic patients. The model provides free retinal risk screenings at local pharmacies, shifting care from hospitals to convenient locations.

The initiative integrates key healthcare stakeholders including pharmacy chains, health clinics, insurance companies, and pharmaceutical partners. Ainnova's AI platform identifies at-risk patients before symptoms appear, enabling early intervention and better clinical outcomes.

Through Ai-Nova Acquisition Corp. (AAC), the companies hold worldwide licensing rights for Ainnova's technology portfolio. The company projects significant revenue growth for 2025 and 2026 as commercial agreements and pilot programs expand across multiple countries.

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech are preparing for a crucial FDA pre-submission meeting scheduled for July 7, 2025. The meeting will focus on discussing the planned clinical trial of Ainnova's Vision AI platform for early detection of diabetic retinopathy.

Through their partnership company Ai-nova Acquisition Corp. (AAC), which holds worldwide licensing rights to Ainnova's technology portfolio, the companies aim to determine critical trial parameters including the number of clinical sites and total patients needed. The pre-submission meeting will be instrumental in obtaining FDA 510(k) clearance to market the Vision AI technology in the United States.

The technology aims to address diabetic retinopathy, the leading cause of preventable blindness worldwide, with potential applications in early detection of other conditions such as Alzheimer's and cardiovascular disease through retinal screening. The FDA engagement is considered crucial for entering the U.S. market and unlocking significant commercial potential.